We assessed the prevalence of von Willebrand's disease (VWD) in patients with objectively con®rmed dysfunctional uterine bleeding. A case±control study was designed to include 38 patients with objectively con®rmed dysfunctional uterine bleeding and 38 age-matched controls with normal menstrual blood loss (MBL). Menorrhagia was de®ned as a mean MBL of greater than 80 ml on three consecutive menses as measured by the alkali haematin method. von Willebrand factor antigen, von Willebrand factor activity (VWF:Ac) and factor VIII:C were measured on three serial venous blood samples 1 week apart. VWD was diagnosed in ®ve of 38 (13%) patients with menorrhagia and one of 38 (2.6%) patients with normal menstrual blood loss. The mean VWF:Ac value was signi®cantly reduced in patients with menorrhagia (mean 6 standard deviation, 84.5 6 26.7 IU/dl versus 103.9 6 34.5 IU/dl; P < 0.01) and this effect persisted after exclusion of patients diagnosed with VWD. Failure to investigate patients for VWD will limit the potential bene®ts of medical therapies such as tranexamic acid or nasal desmopressin [1-desamino-8-D-arginine vasopressin, (DDAVP)] and, in addition, will lead to an increased risk associated with surgical intervention in patients with undiagnosed VWD. Blood Coagul Fibrinolysis 13:89±93 #
Introduction
von Willebrand's disease (VWD) is caused by a qualitative or quantitative defect in von Willebrand factor (VWF) resulting in impaired primary haemostasis [1] . This condition is associated with increased bleeding from mucosal surfaces of the nose and mouth, and with excessive menstrual blood loss (MBL). It is the most common inherited bleeding disorder, with a prevalence in the general population of 1 in 100 [2, 3] .
Menorrhagia is de®ned objectively as . 80 ml MBL [4] . The pathological mechanisms responsible for this condition vary and include polyps, ®broids and endometriosis; however, in 50% of cases, no pathology is detectable and such women are diagnosed as having dysfunctional uterine bleeding [4] . Despite the high prevalence of VWD in the general population, women who are referred for investigation of menorrhagia are not routinely screened for this coagulation disorder. A recent single-centre study identi®ed a high prevalence of VWD (13%) and factor XI (FXI) de®ciency (4%) in patients with menorrhagia [5] . FXI de®ciency is most commonly seen in the Ashkenazi Jewish population, and the prevalence of FXI de®ciency in this study may re¯ected the high prevalence of Jewish patients in the catchment area of this centre [6, 7] . On the contrary, VWD is commonly seen in all patient populations, suggesting that a similar percentage of patients with menorrhagia will have VWD regardless of their ethnic origin [2] . We compared the prevalence of VWD in patients who had excessive MBL with an age-matched cohort of patients with normal MBL.
Methods
We previously assessed MBL in women who were referred to a gynaecology outpatient clinic with symptoms of menorrhagia [8] . MBL was measured by the alkali haematin analysis of sanitary towels on three consecutive menses. Menorrhagia was de®ned as a mean value of greater than 80 ml measured over three consecutive menstrual periods. The exclusion criteria included previous thromboembolic disease or known bleeding disorders. All patients had a normal gynaecological evaluation that included hysteroscopy, endometrial biopsy and cervical smear 3±12 months before measurement of MBL. These patients satis®ed the diagnostic criteria for dysfunctional uterine bleeding, as no explanation was evident for the excessive menstrual bleeding. Five years after the completion of the initial study, 38 patients with objectively con®rmed menorrhagia and 38 controls with objectively con®rmed normal MBL were enrolled in a follow-up study. The controls were women from the initial study who complained of menorrhagia but whose MBL was , 80 ml on each of three consecutive menstrual periods. One interviewer recorded the number of bleeding symptoms, including easy bruising, epistaxis, postoperative bleeding, bleeding post dental extraction and a family history of bleeding. Fifteen millilitres of venous whole blood were collected on three occasions 1 week apart into 0.109 mol/l sodium citrate tubes (Sarstedt Monovette 9NC/3, Numbrecht, Germany). Plasma was separated by centrifugation at 2000 3 g for 20 min at 48C. Factor VIII:C (FVIII:C) was measured by one-stage clotting assay on the ACL3000 coagulometer (Instrumentation Laboratory, Warrington, Cheshire, UK) using factor VIII (FVIII)-de®cient plasma (Sigma Diagnostics, St Louis, Missouri, USA). von Willebrand factor antigen (VWF:Ag) and von Willebrand activity (VWF:Ac) were assayed by enzyme-linked immunosorbent assay (Asserchrom; Diagnostica Stago, Asnieres, France, and Shield Diagnostics, Dundee, UK respectively). In addition, a full blood count and blood group were taken on the initial visit.
Statistical analysis was performed using the Mann±Whitney test using StatView 4.5 (Abacus Concepts, California, USA).
Results
Thirty-eight patients with menorrhagia (mean age AE standard deviation, 49.3 AE 6.1) and 38 agematched controls (age, 48.3 AE 6.2) with normal menstrual blood loss were enrolled in the study. VWD was diagnosed in ®ve out of 38 (13%) patients with menorrhagia as compared with one out of 38 (2.5 %) patients with normal MBL ( Table 1) . Four of the ®ve patients with VWD and menorrhagia underwent a hysterectomy (two vaginal and two abdominal). The mean VWF:Ag, VWF:Ac and FVIII:C were calculated for each patient, and the means of these values were then calculated for both patient groups. VWF:Ac was signi®cantly lower in patients with menorrhagia (84.5 AE 26.7 IU/dl versus 103.9 AE 34.5 IU/dl; P , 0.01), and this persisted after exclusion of those patients diagnosed with VWD (90 AE 24 IU/dl versus 105.5 AE 34 IU/dl; P 0.04) (see Tables 1 and 2) . VWF:Ag and FVIII:C were lower in patients with menorrhagia but this failed to achieve statistical signi®cance (see Tables 1 and 2 ). There was no signi®cant difference in the prevalence Table 3 ).
Discussion
Vessel injury results in a primary haemostatic response, which includes vasoconstriction, platelet adhesion and platelet aggregation. VWF binds to the glycoprotein Ib and IIb/IIIa receptor on platelets and to the subendothelial matrix, and thereby plays a pivotal role in facilitating platelet adhesion and subsequent aggregation [9] . In addition, VWF circulates bound to FVIII:C preventing enzymatic degradation and localizing FVIII to the sites of vessel injury. Therefore, a qualitative or quantitative defect in VWF results in impaired primary haemostasis (platelet adhesion and aggregation) and, in addition, may be associated with a decrease in circulating FVIII:C [10] . The diagnosis of VWD requires laboratory and clinical assessment. The measurement of the VWF pro®le (VWF:Ag, VWF:Ac and FVIII:C) is the primary laboratory investigation for diagnosing VWD [1] . The diagnosis of VWD is complicated by the¯uctuations in the baseline VWF pro®le under the in¯uence of hormonal changes that accompany the menstrual cycle, with lowest values occurring on days 7±14 of the cycle [11, 12] . The diagnosis of VWD has important implications for the management of the patient and their family members. Treatment options include desmopressin infusions, intermediate purity factor concentrate that contains high concentrations of VWF, anti®brinolytic therapy and, more recently, nasal DDAVP [8, 13] . Home treatment with nasal DDAVP, at the time of menstruation, has been associated with a reduction in MBL in patients with VWD [14] .
The subjective diagnosis of menorrhagia has long been recognized as unreliable and the need for more accurate measurement of menstrual blood loss is well documented [15±17]. The gold standard assessment requires the measurement of menstrual blood by laboratory-based techniques such as the alkali haematin method [18, 19] . Due to the dif®culties involved in laboratory-based measurements of menstrual loss, it has been necessary to use less accurate objective measurements, such as pictorial charts, to assess the contribution of inherited bleeding disorders to menorrhagia [5, 19] . To our knowledge, this study represents the ®rst reported data determining the role of VWF in patients and controls in whom MBL was de®ned by an objective laboratory measurement.
Patients who were commenced on HRT in the interval between measurement of MBL and the subsequent laboratory investigations for VWD were not excluded from the study. HRT may have in¯uenced VWF and FVIII:C levels, resulting in an underestimate of the prevalence of VWD. However, the major ®ndings of the study, namely that VWD:Ac is lower and VWD more common in patients with menorrhagia than the general population, is unaffected after the exclusion of patients who were receiving HRT ( Table 3 ). The time interval between the measurement of MBL and subsequent assessment of VWF pro®le is unlikely to effect the difference in VWF:Ac between the two groups as both sets of patients were age matched and exposed to a similar time interval.
VWD was diagnosed in 13% of patients with objectively con®rmed menorrhagia, which is similar to the previously published study [5, 20] . The combined data suggests that there is a true elevation in the prevalence of VWD in women with menorrhagia compared with the general population, and the failure to achieve statistical signi®cance in the current study is likely to re¯ect the small sample size. In addition, the functional VWF assay, which is the most sensitive marker of VWD [10, 21, 22] , was signi®cantly lower in patients with menorrhagia even after exclusion of those patients with VWD. This may have clinical relevance for women with menorrhagia who have VWF in the lower range of normal. It is possible that such women may bene®t from nasal DDAVP or tranexamic acid.
The high prevalence of VWD in the general population and its frequent association with menorrhagia indicates that the investigation of patients with dysfunctional uterine bleeding should include a haemostatic assessment. At the very least, a detailed family and personal history of bleeding history should be obtained from each patient and investigations for VWD performed if there is a family history of VWD, a positive bleeding history such as postpartum haemorrhage or if the patient is due to MBL, Menstrual blood loss; VWF:Ac, von Willebrand factor activity; VWF:Ag, von Willebrand factor antigen; FVIII:C, factor VIII:C; RIPA (low dose), platelet aggregation in presence of low dose ristocetin (0.5 mg/ml).
undergo surgical a procedure. The ®nancial implications of this approach may be minimized by limiting investigations to patients with objectively con®rmed MBL. A positive bleeding history may only become apparent after a signi®cant haemostatic challenge such as dental extraction, surgery or childbirth, and this should be considered in the assessment of patients who have not been exposed to such prior haemostatic challenges.
Conclusion
The measurement of the laboratory investigations for VWF should be incorporated into the diagnostic evaluation of patients referred to gynaecological clinics with dysfunctional uterine bleeding. Failure to identify patients with VWD will limit medical therapeutic options such as nasal DDAVP and tranexamic acid, and in addition will increase the risk of haemorrhagic complications associated with surgical intervention.
